Novogen and Genentech enter in commercialization agreement got glioblastoma multiforme drug candidate

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NOVOGEN Ltd. and Genentech entered an agreement to develop and commercialize GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase pathway. Genentech is a member of the Roche Group. Novogen is an Australian-based company. The lead indication for GDC-0084 is glioblastoma multiforme. GDC-0084 is distinguished from most molecules in the class by its ability to cross...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login